|

IMA 401 (Phase Ib) Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1: 1

Top Sponsors

  • Immatics Biotechnologies GmbH1

Indications

  • Refractory Cancer1
  • Recurrent Cancer1
  • Solid Tumor, Adult1
  • Cancer1

Other1 trial

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.